CF Foundation Awards EPIX Pharmaceuticals $1.25 Million Milestone
January 23, 2008
The CF Foundation announced today it has awarded a $1.25 million milestone payment to EPIX Pharmaceuticals, Inc. (NASDAQ:EPIX), a biopharmaceutical company focused on discovering and developing novel therapeutics. This milestone marks successful completion of the development of a validated model of a full-length Cystic Fibrosis Transmembrane conductance Regulator (CFTR) ion channel protein. A mutation in the CFTR gene that codes for this channel is one of the key factors that ultimately lead to the symptoms, complications and premature mortality in people with CF.
“This is a major milestone in our efforts to use structure-based technologies to design new drugs that could treat CF by addressing the basic defect,” said Robert J. Beall, Ph.D., president and CEO of the CF Foundation.
The collaboration with EPIX, which has focused on discovering potential drug therapies targeting the CFTR ion channel, was recently expanded to allow the company to continue the discovery process, set up a biological lab and prepare for lead optimization.
Click here to read full release.